Platinum-resistant recurrent disease, defined as disease progression within 6 months (≤183 days) after the last platinum-based chemotherapy.
At least one measurable lesion per RECIST v1.1.
ECOG performance status of 0 or 1.
Expected survival ≥ 12 weeks.
Adequate organ and bone marrow function.
Negative pregnancy test for women of childbearing potential, and agreement to use effective contraception.
You may not be if
Prior treatment with CLDN6-targeting therapy or topoisomerase I inhibitors (e.g., topotecan, trastuzumab deruxtecan).
Active or untreated central nervous system (CNS) metastases or carcinomatous meningitis. (Patients with stable, treated CNS metastases may be eligible).
Clinically significant cardiovascular disease, including QTc ≥ 470 ms, LVEF \< 50%, or uncontrolled hypertension.
Active infections (e.g., HBV, HCV, HIV, tuberculosis, syphilis).
Active or history of autoimmune diseases requiring systemic treatment.
Severe liver disease (Child-Pugh B or C), uncontrolled diabetes, or other severe medical conditions that may interfere with the study.